GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Destiny Pharma PLC (LSE:DEST) » Definitions » Insider Ownership

Destiny Pharma (LSE:DEST) Insider Ownership : 13.74 % (As of Jun. 13, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Destiny Pharma Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Destiny Pharma's insider ownership is 13.74%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Destiny Pharma's Institutional Ownership is 6.36%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Destiny Pharma's Float Percentage Of Total Shares Outstanding is 0.00%.


Destiny Pharma Insider Ownership Historical Data

The historical data trend for Destiny Pharma's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Destiny Pharma Insider Ownership Chart

Destiny Pharma Historical Data

The historical data trend for Destiny Pharma can be seen below:

2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30 2024-05-31
Insider Ownership 13.74 13.74 13.78 13.78 13.78 13.78 13.78 13.77 13.77 13.74

Destiny Pharma Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.


Destiny Pharma (LSE:DEST) Business Description

Traded in Other Exchanges
Address
Unit 36, Sussex Innovation Centre, Science Park Square, Falmer, Brighton, GBR, BN1 9SB
Destiny Pharma PLC is a clinical-stage biotechnology company which is focused on the development of medicines for the treatment of infectious disease. It is developing drugs for the prevention and treatment of infections caused by Antibiotic-Resistant (AR) bacteria. It is involved in developing XF-73 Dermal for the treatment of skin infections of antibiotic-resistant bacteria, XF-73 Nasal for prevention of post-surgical staphylococcal infection, XF Throat for prevention of staphylococcal hospital/ventilator-associated pneumonia infection.

Destiny Pharma (LSE:DEST) Headlines

No Headlines